메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Noul Secures FDA Registration for Cervical Cancer Diagnostic Cartridge

FDA registration fulfills requirements for U.S. market entry Initial shipments to Europe and Latin America to begin with pre-approved countries YONGIN, South Korea, Sept. 23, 2025 -- Noul Co., Ltd. (CEO: David Lim), a medical AI company specializing in blood and cancer diagnostics, announced that FDA registration has been completed for its cervical cancer diagnostic cartridge miLab™ Cartridge CER and clearing agent SafeFix™ CER, both core components of the company's cervical cancer diagnostic solution miLab™ CER. With this registration, Noul has fulfilled
- 김갑성 기자
- 2025-09-23 21:00
케민인더스트리즈, CJ Bio의 자회사 CJ유텔바이오텍 인수

효소 및 발효를 전문으로 하는 바이오테크 회사 인수로 케민의 전 세계 효소 생산능력이 획기적으로 증가할 전망이다 아이오와주 디모인 및 상하이, 2025년 9월 23일 -- 제품과 서비스를 통해 80%에 달하는 전 세계 소비자의 지속적인 삶의 질 혁신에 매진하는 세계적인 원료 제조업체 케민인더스트리즈(Kemin Industries)가 효소와 발효를 전문으로 하는 CJ Bio의 자회사 CJ유텔바이오텍(CJ Youtell Biotech)을 인수한다. 이 전략적 결정으로 케민은 동물 사료, 식품, 양식업, 섬유, 제지 및 펄프, 바이오 연료 산업 등의 시장에서 효소 혁신 분야 세계 선두 기업으로서 더욱 견고한 입지를 만들 전망이다. 이번 인수로 케민은 CJ유텔 발효 공장과 효소 제품 포트폴리오의 완전 소유권을 갖게 된다. CJ유텔은 전략적 차원에서 중국 산둥성과 후난성에 건립한 공장을 비롯해 세계 정상급 발효 플랫폼을 케민에 지원하게 된다. 새로운 인프라를 확보함에 따라 케민은 효소 사업을 확장해 환경친화적인 첨단 효소 기술로 생산한 원료를 전 세계 고객에게 직접 공급할 수 있게 됐다. 케민인더스트리즈의 사장이자
- 김갑성 기자
- 2025-09-23 21:00
HKeyBio Lauched the Most Comprehesive Non-human Primate Autoimmune & Allergic Disease Model Matrix to Redefining Clinical Translation

BOSTON and SUZHOU, China, Sept. 23, 2025 -- HKeyBio, a CRO specializing in preclinical and translational autoimmune-drug development, today announced the launch of HKEY-NHP-MATRIX2.0, a next-generation platform designed to improve the reliability of translating novel autoimmune and allergy therapies from preclinical research to clinical success. Platform Highlights Broad Primate Disease Model LibraryThe platform includes over twenty non-human primate (NHP) models spanning autoimmune and allergic diseases in four major categories: dermatology, respiratory, gastroenterology, an
- 김갑성 기자
- 2025-09-23 20:35
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SALT LAKE CITY and BOSTON, Sept. 23, 2025 -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad's advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS' broad, decentralized network of more than 800
- 김갑성 기자
- 2025-09-23 20:01
女性の鉄欠乏症に生物学的イノベーションが効く - 今や3大陸で認知されている

STOCKHOLM, 2025年9月23日 -- 女性の鉄吸収を改善するよう設計された健康ソリューションが国際的な称賛を集め、欧州、北米、そしてアジアで最高賞を受賞しました。2025年におけるこの3つの認定は、より効果的で忍容性の高い鉄補給の必要性に対する世界的な意識の高まりを浮き彫りにしています。バイオティクス・ソリューション企業のProbi社が開発したのコンセプトには、臨床研究済みのプロバイオティクス菌株、ラクリプランティバチルス・プランタルム 299v (LP299V®)が含まれています。鉄分と組み合わせると、LP299V®は鉄分の吸収を高め、従来のサプリメントに関連する消化器系の副作用を軽減します。鉄分不足は世界中で最も差し迫った栄養的課題の一つであり、女性の30%以上が影響を受けています。単に鉄分を追加するのではなく、Probiの特許技術を持つ菌株は、体がより効果的に鉄分を吸収できるようにサポートします。LP299V®は2つの重要な方法で鉄の取り込みをサポートする：鉄分を吸収可能な形で保持し、鉄を変換する酵素の体内での発現を増加させることによって。これにより、食品やサプリメントからの吸収が改善されます。「1年間で3大陸からの認識は、この問題の緊急性と、科学に裏
- 김갑성 기자
- 2025-09-23 18:58
Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress

CHENGDU, China, Sept. 23, 2025 -- The 2025 European Society for Medical Oncology (ESMO) Congress will take place in Berlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) will present results from multiple clinical studies at the congress, including data from its TROP2 ADC sacituzumab tirumotecan (sac-TMT), HER2 ADC A166 (trastuzumab botidotin), and CLDN18.2 ADC SKB315. Among these, two Phase III clinical studies of sac-TMT were selected for the Latest Breakthrough Abstracts (LBA) and presented as oral reports,
- 김갑성 기자
- 2025-09-23 17:03
Economist Impact's 5th edition Future of Health Asia returns to Singapore amid rising technological disruption, chronic disease burdens and international trade tensions

Singapore to host 500 health, science and policy leaders on October 16th to address pressing issues in the Asia-Pacific healthcare sector. Members of the media are invited to register here. SINGAPORE, Sept. 23, 2025 -- Convening on October 16th at the Four Seasons Hotel, the 5th edition Future of Health Asia will bring together 500 senior leaders from healthcare, government and patient advocacy to examine the impact of rising technological disruptions, rising pressure of chronic diseases and global economic uncertainty. The Asia-Pacific's healthcare secto
- 김갑성 기자
- 2025-09-23 14:50
Mindray Unveils Project 2030 and Re-writes the Future of Women's Health Ultrasound at ISUOG

CANCUN, Mexico, Sept. 23, 2025 -- On September 15th, at ISUOG 2025 World Congress in Cancun, Mexico, Mindray unveiled Project 2030, an initiative to improve global access to ultrasound technology. The project was launched to an international audience of leading specialists, capping a conference that featured Mindray's OBG solutions as a key highlight. Mindray's Women Healthcare Ultrasound Solution Shines on the Stage During the congress, Prof. Savino Gil Pugliese (Head of Fetal Surgery, University Hospital of Córdoba) and Prof. Roberto Albinagorta (ISUOG Ambassado
- 김갑성 기자
- 2025-09-23 13:48
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year

SHANGHAI, Sept. 23, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been selected as a constituent company of the FTSE4Good Index Series, marking the fifth consecutive year the company has been recognized by FTSE Russell for outstanding sustainability performance. The FTSE4Good Index Series, launched in 2001 by FTSE Russell (now part of the London Stock Exchange Group), is a family of equity indices designed to measure the performance of companies demonstrating strong Environmental, Social
- 김갑성 기자
- 2025-09-23 12:00
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC

CHENGDU, China, Sept. 23, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the treatment of adult patients with RET-fusion positive locally advanced, or metastatic non-small cell lung cancer (NSCLC). This acceptance for review is based on the positive results from
- 김갑성 기자
- 2025-09-23 10:22

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-10-19_SUN

2025-10-18_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 19일 03시 20분